MC
VNDA icon

Meteora Capital’s Vanda Pharmaceuticals VNDA Stock Holding History

Meteora Capital’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-90,900
Closed -$426K – 168
2024
Q3 		$426K Buy
+90,900
New +$487K 0.12% 103

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Meteora Capital's VNDA Position: Q4 2024 in Review

Meteora Capital sold out of Vanda Pharmaceuticals (VNDA) in Q4 2024, closing a stake of 90,900 shares — an estimated $426K sold.

Meteora Capital first reported a position in VNDA in Q3 2024 and held it in 1 quarter. The position peaked at $426K in Q3 2024. 146 funds tracked by Wall St. Rank hold VNDA as of Q4 2024.

  • Meteora Capital reported no remaining Vanda Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Meteora Capital sold 90,900 Vanda Pharmaceuticals shares in Q4 2024, an estimated $426K.
  • Meteora Capital first reported a position in Vanda Pharmaceuticals in Q3 2024 and held it in 1 quarter.
  • Meteora Capital's Vanda Pharmaceuticals position peaked at $426K in Q3 2024.
  • 146 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q4 2024.

Based on Meteora Capital's 13F filing for Q4 2024, filed 14 Feb 2025.